Euroopa Liit - eesti - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - immunosupressandid - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz saab antud monotherapy juhul, talu metotreksaati või kui jätkuv ravi metotreksaadi on kohatu. adalimumab on näidanud, et vähendada määra progressioon ühise kahju, mida mõõdetakse x-ray ja parandab füüsilist funktsiooni, kui antud koos metotreksaadi. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz saab antud monotherapy juhul, talu metotreksaati või kui jätkuv ravi metotreksaadi on kohatu. adalimumab ei ole uuritud patsientidel vanuses alla 2 aastat. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab on näidanud, et vähendada määra progressioon perifeersete ühine kahju, mida mõõdetakse x-ray patsientidel polüartikulaarse sümmeetriline alatüüpide haiguse ja füüsilise funktsiooni parandamiseks. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - munasarjade kasvajad - antineoplastilised ained - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca on näidustatud monotherapy hooldus-ravi täiskasvanud patsientidel, kellel on plaatina-tundlik taastekkinud kõrge kvaliteediga epiteeli munasarja -, munajuha-või esmase peritoneaaldialüüsi vähi, kes on vastuseks (täielik või osaline) platinum põhineva keemiaravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombotsütopeenia - antihemorraagilised ained - doptelet on näidustatud ravi raske trombotsütopeenia täiskasvanud patsientidel, kellel on krooniline maksahaigus, kes on kavandatud läbima invasiivne protseduur. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidid, immunoglobuliinid).

Eesti - eesti - Ravimiamet

synthon b.v. - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 7tk; 20mg 80tk; 20mg 50tk; 20mg 100tk; 20mg 28tk; 20mg 14tk; 20mg 112tk; 20mg 10tk; 20mg 20tk; 20mg 15tk; 20mg 56tk; 20mg 90tk; 20mg 70tk; 20mg 40tk; 20mg 30tk

Eesti - eesti - Ravimiamet

alfred e. tiefenbacher gmbh & co. kg - rosuvastatiin - õhukese polümeerikattega tablett - 10mg 98tk; 10mg 42tk; 10mg 28tk; 10mg 60tk; 10mg 50tk; 10mg 90tk; 10mg 14tk; 10mg 56tk; 10mg 30tk

Eesti - eesti - Ravimiamet

novartis baltics sia - letrosool - õhukese polümeerikattega tablett - 2,5mg 28tk; 2,5mg 10tk; 2,5mg 100tk

Eesti - eesti - Ravimiamet

alfred e. tiefenbacher gmbh & co. kg - rosuvastatiin - õhukese polümeerikattega tablett - 5mg 100tk; 5mg 90tk; 5mg 28tk; 5mg 60tk; 5mg 50tk; 5mg 7tk; 5mg 20tk; 5mg 14tk; 5mg 98tk; 5mg 42tk

Eesti - eesti - Ravimiamet

alfred e. tiefenbacher gmbh & co. kg - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 20tk; 20mg 100tk; 20mg 42tk; 20mg 28tk; 20mg 98tk; 20mg 84tk; 20mg 90tk; 20mg 30tk

Eesti - eesti - Ravimiamet

globalex pharma oÜ - letrosool - õhukese polümeerikattega tablett - 2,5mg 100tk; 2,5mg 28tk; 2,5mg 14tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - letrosool - õhukese polümeerikattega tablett - 2,5mg 60tk; 2,5mg 30tk; 2,5mg 100tk; 2,5mg 10tk; 2,5mg 98tk; 2,5mg 84tk; 2,5mg 28tk; 2,5mg 90tk; 2,5mg 14tk